Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In vitro analysis of the susceptibility of HIV-1 subtype A and CRF01_AE integrases to raltegravir.

International journal of antimicrobial agents - 1 Aug 2014

Bellecave Pantxika, Malato Laurent, Calmels Christina, Reigadas Sandrine, Parissi Vincent, Andreola Marie-Line, Fleury Hervé

Abstract excerpt

The antiviral efficacy of raltegravir (RAL) has been proven against human immunodeficiency virus type 1 (HIV-1) subtypes B and C but remained to be determined against other subtypes. Therefore, the enzymatic activities as well as RAL resistance of HIV-1 subtype A and CRF01_AE integrases (INs) were investigated. Previously published subtype A and CRF01_AE IN sequences from RAL-naïve patients were aligned to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to HIV-1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Integrase

Share to Inhibitory Concentration 50

Share to Microbial Sensitivity Tests

Share to Mutant Proteins

Share to Pyrrolidinones

Share to Raltegravir Potassium

Source

Identifiers

PMID: 24935032
DOI: 10.1016/j.ijantimicag.2014.04.013

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In vitro analysis of the susceptibility of HIV-1 subtype A and CRF01_AE integrases to raltegravir.PMID 24935032Read ↗

The HIV-1 Integrase Mutations Y143C/R Are an Alternative Pathway for Resistance to Raltegravir and Impact the Enzyme FunctionsSemantic proximity Read ↗

Ex-vivo antiretroviral potency of newer integrase strand transfer inhibitors cabotegravir and bictegravir in HIV type 1 non-B subtypes.Semantic proximity Read ↗

In-vitro phenotypic susceptibility of HIV-1 'non-B' integrase inhibitors naive clinical isolates to dolutegravir and raltegravir.Semantic proximity Read ↗

Comparative biochemical analysis of HIV-1 subtype B and C integrase enzymes.Semantic proximity Read ↗

The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutationSemantic proximity Read ↗

Prevalence of primary resistance mutations to integrase inhibitors in treatment-naïve and -experienced patients infected with B and non-B HIV-1 variants.Semantic proximity Read ↗

Structure-analysis of the HIV-1 integrase Y143C/R raltegravir resistance mutation in association with the secondary mutation T97A.Semantic proximity Read ↗

HIV-1 group O resistance pathway with raltegravir is similar to HIV-1 group M.Semantic proximity Read ↗

Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro.Semantic proximity Read ↗

Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes.Semantic proximity Read ↗

Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy.Semantic proximity Read ↗

Drug resistance mutations of HIV type 1 non-B viruses to integrase inhibitors in treatment-naive patients from sub-saharan countries and discordant interpretations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.